A weak contact profile can mis-scope the biological evaluation before the evidence is reviewed.
Start by defining what each relevant device component contacts, how contact occurs, and the expected cumulative exposure. Those facts inform which biological effects must be addressed; they do not create an automatic testing list.
Many biological evaluations go off track before any testing, literature review, or waiver logic begins. The root problem is often simple: the device was classified too broadly, too narrowly, or as a single contact profile when the design actually contains multiple contact situations.
Why Contact Classification Comes First
Contact classification is one of the first substantive decisions in a BEP. Together with the device's materials, processing, clinical use, patient population and available evidence, it helps identify which biological effects need to be addressed. If the contact profile is wrong, later evidence decisions become harder to defend.
Describe the Nature of Contact
Map direct and indirect patient contact component by component. FDA's public endpoint framework groups devices broadly as surface-contacting, externally communicating, or implant devices, with more specific contact sites within those groups. The biological implications differ substantially for intact skin, mucosa, breached surfaces, tissue, bone, blood-path indirect contact and circulating blood.
- Surface contact devices: intact skin, mucosal membranes, or breached/compromised surfaces.
- External communicating devices: blood path, indirect; tissue/bone/dentin; or circulating-blood contact.
- Implants: tissue or bone contact, or blood contact; duration is assessed separately.
Document Duration and Cumulative Exposure
The same nature of contact can lead to different biological questions as exposure changes. FDA's public endpoint pages use the following duration bands; treat them as FDA categories rather than universal substitutes for a device-specific exposure analysis.
- Limited: cumulative exposure of 24 hours or less.
- Prolonged: more than 24 hours and up to 30 days.
- Long-term: more than 30 days.
Use the Contact Profile to Frame Endpoint Decisions
Once contact nature and duration are established, use them with material, process and clinical-use information to identify biological effects that need to be addressed. A limited-contact skin device may present a narrower set of questions than a long-term implant, but neither classification alone proves which studies are necessary. Existing data, chemical characterization, toxicological assessment, clinical or post-market information, testing and a documented rationale are all possible evidence routes.
Continue with the ISO 10993 biological endpoint selection guide for a risk-based map from contact profile to endpoint questions and evidence options, including the important 2026 differences between ISO, FDA and EU status.
Where Teams Commonly Get It Wrong
- Using the product name as the classification: for example, calling something a catheter without unpacking the actual tissue and blood-contact profile.
- Ignoring cumulative exposure: repeated or intermittent contact needs a documented duration calculation; a single-use time alone may not represent the patient's full exposure.
- Treating the whole device as one contact profile: different components may contact different tissues and require different endpoint logic.
- Skipping change impact: a design, indication, or material change can alter the classification and therefore the whole endpoint strategy.
Multi-Component Devices Need More Care
Combination or multi-material devices often need separate classification logic for distinct components. A device with one part in circulating blood and another part implanted in tissue should not automatically inherit a single simplified endpoint set. That kind of shortcut is a common source of reviewer questions.
When in doubt, classify the patient-contacting components explicitly and show the reasoning. Reviewers are much more comfortable with a visible, defensible classification path than with a short conclusion that skips the logic.
What a Strong BEP Does with Contact Classification
A strong BEP does not just state the classification result. It explains how the contact profile was determined, how cumulative duration was considered, whether different components were assessed separately, and how that led into the final endpoint strategy.
Official sources checked August 9, 2026
- ISO 10993-1:2025 — current international standard for biological-safety evaluation within risk management
- FDA device-category endpoint framework — FDA states that its endpoint tables are a framework, not a testing checklist
- FDA contact-duration periods — limited, prolonged and long-term categories
- FDA recognition record 2-313 — partial recognition of ISO 10993-1:2025 entered May 25, 2026
Why this perspective is practical
Arvind Rathore is the founder of MedDev Advisory, where his work focuses on ISO 10993 biological-evaluation strategy and documentation. Before establishing the practice, he was a Marie Skłodowska-Curie Early Stage Researcher at INSERM U1026 Biotis within the ImplantSens network. His research covered implantable electrochemical biosensors, cytotoxicity, oxidative stress, sterilization effects and biomaterial–cell interactions, with research placements in France, Germany and Sweden. Peer-reviewed work in Bioelectrochemistry and Advanced Sensor Research also informs his evidence-led approach. Read more about Arvind Rathore.
Need help confirming the right contact classification and endpoint scope before drafting the BEP?
Use the next step that fits best: discuss the project directly or continue through the insights library for related guidance.